Driver Response to Hydrogen Fuel Cell Buses in a Real-World Setting Study of a Northern California Transit Bus Fleet

被引:7
|
作者
Lipman, Timothy E. [1 ]
Gray-Stewart, Ananda L. [1 ]
Lidicker, Jeffrey [2 ]
机构
[1] Univ Calif Berkeley, Transportat Sustainabil Res Ctr, Berkeley, CA 94704 USA
[2] Michigan Technol Univ, Dept Civil & Environm Engn, Houghton, MI 49931 USA
关键词
Fuel economy;
D O I
10.3141/2502-06
中图分类号
TU [建筑科学];
学科分类号
0813 ;
摘要
This study examined bus drivers' acceptance of fuel cell electric buses in Alameda-Contra Costa Transit in the San Francisco Bay Area of California. Of the 145 surveys issued, 47 drivers completed a written survey, for a 32% response rate. The study focused on a key attribute for potential success of alternative urban bus technology: the driver acceptance factor. Technology performance flaws that are undesirable or annoying to the bus drivers may also be disruptive to passengers. Furthermore, because of using the buses throughout their full duty cycle, drivers are in a unique position to identify key opportunities to improve the new technology options as they emerge and evolve. The study found that drivers, in general, rated the hydrogen fuel cell buses to be at the same or better performance than diesel buses for handling, ride quality, acceleration, and braking. For quiet operation, the drivers rated the new buses as excellent. When asked how they liked the experimental hydrogen fuel cell buses, drivers responded at just above neutral, with the most common response being "the same" as diesel buses followed by "much better." Those drivers who said that they considered fuel economy when purchasing a vehicle liked the fuel cell buses more. Older drivers preferred the diesel buses, and male drivers preferred the new fuel cell buses. Perceptions of safety were mixed, with some drivers expressing safety concerns independent of how much training they had received.
引用
收藏
页码:48 / 52
页数:5
相关论文
共 50 条
  • [31] Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China
    Gong, L.
    Chen, J. Z.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S400 - S401
  • [32] Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients
    Ruiz, Gonzalo
    Enrico, Diego
    Mahmoud, Yamil D.
    Ruiz, Alan
    Cantarella, Maria Florencia
    Leguina, Laura
    Barberis, Mariana
    Bena, Asuncion
    Brest, Esteban
    Starapoli, Solange
    Bertelli, Andrea Mendoza
    Tsou, Florencia
    Pupareli, Carmen
    Coppola, Maria Pia
    Scocimarro, Alejandra
    Sena, Susana
    Levit, Patricio
    Perfetti, Aldo
    Aman, Enrique
    Girotti, Maria Romina
    Arrieta, Oscar
    Martin, Claudio
    Salanova, Ruben
    THORACIC CANCER, 2024, 15 (11) : 895 - 905
  • [33] Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
    Chouaid, Christos
    Dujon, Cecile
    Do, Pascal
    Monnet, Isabelle
    Madroszyk, Anne
    Le Caer, Herve
    Auliac, Jean Bernard
    Berard, Henri
    Thomas, Pascal
    Lena, Herve
    Robinet, Gilles
    Baize, Nathalie
    Bizieux-Thaminy, Acya
    Fraboulet, Gislaine
    Locher, Chrystele
    Le Treut, Jacques
    Hominal, Stephane
    Vergnenegre, Alain
    LUNG CANCER, 2014, 86 (02) : 170 - 173
  • [34] EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
    Dixmier, A.
    Debieuvre, D.
    Raspaud, C.
    Auliac, J. B.
    Benoit, N.
    Bombaron, P.
    Asselain, B.
    Dumont, A.
    Lamoureux, P.
    Goyard, N.
    Moro-Sibilot, D.
    Perol, M.
    Barlesi, F.
    Valette, C. Audigier
    ANNALS OF ONCOLOGY, 2018, 29 : 532 - 532
  • [35] CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting
    Rabinowits, G.
    Homsi, J.
    Park, S. J.
    Khushanlani, N.
    Panella, T.
    Ellison, D. M.
    Gentry, R. W.
    Venna, S. S.
    Strasswimmer, J.
    Zuniga, R. M.
    Chandra, S.
    Ruiz, E. S.
    Migden, M. R.
    Ibrahim, S.
    Mehta, N.
    He, X.
    Zhang, H.
    Gillis, K. A.
    Pouliot, J-F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S925 - S926
  • [36] Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study
    Kato, Junji
    Namikawa, Kenjiro
    Uehara, Jiro
    Nomura, Motoo
    Nakamura, Yasuhiro
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Kiniwa, Yukiko
    Nakamura, Yoshiyuki
    Miyagawa, Takuya
    Matsushita, Shigeto
    Takenouchi, Tatsuya
    Hatta, Naohito
    Ohno, Fumitaka
    Maeda, Taku
    Fukushima, Satoshi
    Yamazaki, Naoya
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (04) : 594 - 596
  • [37] Real-World Overall Response Rate (ORR) of Diffuse Large B-Cell Lymphoma with Polatuzumab Vedotin-Based Theraphy, a Multicentric Study in Mexico
    Rodriguez Mejorada, Silvia Margarita
    Villalobos Prieto, Alberto
    Ceballos Lopez, Adrian Alejandro
    Reynoso Gomez, Eduardo Edmundo
    Sandoval Villa, Celia Carela
    Tripp Villanueva, Francisco Jose
    Cruz Contreras, Diego
    Guzman Hernandez, Alicia Elizabeth
    Lopez Navarro, Omar Genaro
    Neme Yunes, Yvette
    Perez Ramirez, Oscar De Jesus
    Rico Curiel, Enrique
    Barbosa Loria, Diego Mauricio
    BLOOD, 2023, 142
  • [38] IMPACT RCC REAL-WORLD STUDY: ECONOMIC IMPACT OF EARLY PROGRESSION AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS IN FIRST-LINE SETTING
    Bhanegaonkar, A.
    Pandya, S.
    Kim, R.
    Zheng, Y.
    Dieyi, C.
    Krulewicz, S.
    Kasturi, V
    Liu, F. X.
    Hutson, T. E.
    VALUE IN HEALTH, 2020, 23 : S42 - S43
  • [39] Treatment patterns and clinical outcomes of resectable clinical stage III non-small cell lung cancer in a Japanese real-world setting: Surgery cohort analysis of the SOLUTION study
    Tsuboi, Masahiro
    Murakami, Haruyasu
    Harada, Hideyuki
    Sobue, Tomotaka
    Kato, Tomohiro
    Atagi, Shinji
    Tokito, Takaaki
    Mio, Tadashi
    Adachi, Hirofumi
    Kozuki, Toshiyuki
    Sone, Takashi
    Seike, Masahiro
    Toyooka, Shinichi
    Kitagawa, Hiroshi
    Koto, Ryo
    Yamazaki, Satoshi
    Horinouchi, Hidehito
    THORACIC CANCER, 2024, 15 (20) : 1541 - 1552
  • [40] Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting
    Spira, Alexander I.
    Korytowsky, Beata
    Gao, Sara
    Dubois, Renard
    Wilson, Thomas
    Osterland, Andrew
    Shi, Junxin
    Conkling, Paul R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)